Getting your player ready...
LEXINGTON, Mass. — Amag Pharmaceuticals Inc. said Wednesday it will buy drugmaker Allos Therapeutics Inc. for stock valued at about $268 million in a deal designed to bolster Amag’s commercial portfolio and cut costs.
Amag makes Feraheme for the treatment of iron-deficiency anemia in adults with chronic kidney disease. Allos, based in Westminster, produces the T-cell lymphoma treatment Folotyn.
The companies estimate that they can save between $55 million and $60 million annually by eliminating costs, most of which will be realized in the first fiscal year after the deal closes.
